Seminars in Oncology
Volume 36, Issue 5 , Pages 432-438, October 2009

Testicular Cancer: A Prototypic Tumor of Young Adults

  • Brandon Hayes-Lattin

      Affiliations

    • Knight Cancer Institute, Oregon Health and Science University, Portland, OR
    • Corresponding Author InformationAddress correspondence to Brandon Hayes-Lattin, MD, 3181 SW Sam Jackson Park Rd, Mailcode L586, Portland, OR 97239
  • ,
  • Craig R. Nichols

      Affiliations

    • Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR

Testicular cancer is the most common solid tumor among males in the 20- to 39-year age range. Moreover, testicular cancer has unique biological associations, clinical features, and psychosocial impacts that establish this tumor as a prototypic malignancy of young adults. The biology of testicular germ cell tumors after puberty is distinctive. Epidemiologic patterns of testicular cancer suggest etiologic factors that may be congenital, racial, and geographic. The clinical management of a cancer common among young adults, but rare among adults in general, requires expertise so as not to jeopardize the high rates of survivorship associated with modern therapy. The concurrent but separate development of staging, prognostic systems, and treatment recommendations between the fields of pediatric and adult oncology highlights the need for increased integration and cooperation across these subspecialties. The high rate of survival, combined with the need for long-term monitoring for relapse or late effects, demonstrates the challenge of delivering longitudinal care in this mobile and active young adult population.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(09)00141-9

doi:10.1053/j.seminoncol.2009.07.006

Seminars in Oncology
Volume 36, Issue 5 , Pages 432-438, October 2009